Factors affecting the uptake of prenatal diagnosis for sickle cell disease

Mary Petrou, Maura Brugiattelli, R H T Ward, Bernadette Modell

Abstract

Between 1979 and 1990, 170 couples at risk of having children with sickle cell disease, resident in the UK and with a continuing pregnancy, were referred for counselling at the University College Hospital Perinatal Centre. Approximately 50% of the couples, including those where one partner actually had sickle cell disease, requested prenatal diagnosis. This was requested in 82% of pregnancies when the mother was seen in the first trimester of pregnancy and in 49% when she was seen in the second trimester. More than 90% of referred couples who already had an affected child requested prenatal diagnosis. The type of sickle cell disease involved and ethnic group also influenced choice. These results show the importance of detecting and counselling couples at risk before pregnancy whenever possible.

(*J Med Genet* 1992;29:820-3)

The objective of screening for carriers of recessively inherited diseases is to inform them of possible genetic risk, and to allow couples who actually are at risk an informed choice among the available options.¹ These include prenatal diagnosis. Carrier screening for haemoglobin disorders (the thalassaemias and sickle cell disease) is now standard practice in antenatal clinics in the UK.² When a carrier woman is detected, her partner is invited to come for testing: if he also carries a haemoglobinopathy trait, the couple may be at risk. Couples where both partners are carriers have a 25% risk of an affected infant in each pregnancy: couples where one has a major (homozygous) disorder and one is a carrier have a 50% risk.

Most couples at risk for having children with α or β thalassaemia major choose prenatal diagnosis and selective abortion of affected fetuses.^{3,4} By contrast, the decision for or against prenatal diagnosis for sickle cell disease can be very difficult, as it includes a range of conditions of variable and unpredictable severity. Sickle cell anaemia (Hb SS) and Hb SD disease are usually the most severe, haemoglobin S/ β thalassaemia is usually intermediate, and Hb SC disease is usually the mildest.^{5,6} Clearly, couples at risk require expert counselling.

The availability and quality of counselling for risk of sickle cell disease has been improving steadily in the UK since training courses were started at the Brent sickle cell centre in 1981, and subsequently at other centres. Cur-

rently, countrywide, 35 trained counsellors are working in 23 Health Authorities, 12 of them in six Health Authorities in North London (E Anionwu, personal communication). In England and the United States, about a third to a half of at risk couples counselled by a trained person request prenatal diagnosis.^{7,8} This suggests that a review of a series of cases may cast light on factors that influence the choices informed couples make. Here we report the results of a review of the records of pregnant women at risk for having children with sickle cell disease counselled at the UCH Perinatal Centre, which offers a regional and national service for prenatal diagnosis of haemoglobin disorders. The results show that choice is influenced by the nature of the genetic risk, ethnic group, experience of an affected family member, and the possibility of diagnosis in the first trimester of pregnancy. Clearly, couples at risk for having children with inherited diseases should be identified and provided with expert counselling either before or at the earliest possible stage of pregnancy.

Methods

From 1979 to the end of 1990, 170 couples resident in the UK and at risk for having children with sickle cell disease attended the Perinatal Centre at University College Hospital for counselling and the offer of prenatal diagnosis. Almost all were resident in the North-East or North-West Thames Regions, though many of African extraction were long term visitors for educational purposes, and primarily resident in Africa. All the women were already pregnant: most were seen within a few days of referral and all within a week. All were seen by one of two counsellors (MP or BM) who have a very similar approach. The additional risk of miscarriage associated with chorionic villus sampling (CVS) or fetal blood sampling at our centre is given as 1 to 2%. Written information is provided at the end of the session (copies available on request from Dr Petrou), and objectivity is ensured by putting couples in touch with support associations (for example, the Sickle Cell Society) and providing publications produced or approved by the associations. Standard notes kept for each couple seen include the information provided by the referring centre, ethnic group, week of gestation when the woman was first seen, results of subsequent investigations, details of how and when the couple found they were carriers and heard of prenatal diagnosis, full obstetric history, and details of the choice made (with reasons when given), as well as

Perinatal Centre,
Department of
Obstetrics and
Gynaecology,
University College
and Middlesex School
of Medicine,
University College
London, 86-96 Chenies
Mews, London
WC1E 6HX.
M Petrou
B Modell

Thalassaemia Unit,
Reggio Calabria
Hospital, Italy.
M Brugiattelli

Department of
Obstetrics and
Gynaecology,
University College
and Middlesex School
of Medicine,
University College
London.
R H T Ward

Correspondence to
Dr Petrou.

Received 11 February 1992.
Revised version accepted
5 May 1992.

details of each prenatal diagnosis. This information set was complete for most, but not all, cases. The data available were tabulated on a yearly basis.

Results

Table 1 shows that the annual number of referrals of couples at risk for sickle cell disease is rising steadily. There were very few before first trimester prenatal diagnosis was introduced in 1982 to 1984, and there has been a steady increase since 1988, as trained counsellors have become available in the North-West and North-East Thames Regions. Fifty-two percent of the couples seen requested prenatal diagnosis, and there has been no clear change in this proportion with time. A majority of these have been performed in the first trimester, in time for suction termination of pregnancy if requested.

Table 2 shows that over half of the couples at risk for SS disease, about half of those at risk for Hb S/ β thalassaemia, and only a small proportion of those at risk for haemoglobin SC disease requested prenatal diagnosis. Eight of 14 couples, who were at 50% risk because one partner had sickle cell disease, requested it.

More people of African than of Afro-Caribbean origin chose prenatal diagnosis (table 3).

Table 1 Referrals for counselling for prenatal diagnosis of sickle cell disease by year (170 couples with 188 pregnancies).

Year	At risk referrals	Not having PND (women)	PND requested (pregnancies)	PNDs completed before end of 13th week	
				No	%
1979	3	1	2		
1980	5	2	3		
1981	2	0	2		
1982	10	6	4	2)	
1983	3	0	3	1)	
1984	16	3	13	7)	53
1985	7	4	3	1)	
1986	16	7	9	7)	
1987	19	5	14	9	64
1988	26	12	14	12	86
1989	43	23	20	16	80
1990	38	16	22	19	86
Total	188	79	109 (89 women)	74	68

PND = prenatal diagnosis.

Table 2 Nature of risk and choice of PND.

Risk of fetus	No of couples seen	Choosing PND	
		No	%
SS*	121	70	58
S/ β thal	17	8	47
SC	18	3	17
50% risk	14	8	57
Total	170	89	52

* Includes two cases of SD.
SS v S/ β thal $\chi^2 = 0.24$, $p = \text{NS}$.
SS v SC $\chi^2 = 10.26$, $p = < 0.01$.

Table 3 Ethnic group and choice of PND.

	Ethnic group				Total
	Afro-Caribbean	Mixed	African	Other*	
No	45	9	107	9	170
Choosing PND	16†	4	61†	8	89
% choosing PND	36	44	57	89	52

Mixed = Afro-Caribbean $\times$ African.

* Mostly Cypriots or Indians.

† $\chi^2 = 5.65$, $p < 0.02$.

'Others' were mostly of Cypriot or Indian origin, most were at risk for Hb S/ β thalassaemia, and most chose this option.

Table 4 shows that 94% of referred women who already had one or more children with sickle cell disease chose prenatal diagnosis and most terminated the pregnancy when sickle cell disease was diagnosed. Uptake was lower among couples without a previous affected child, and lowest among primigravidae.

Table 5 summarises the women's previous obstetric history (before counselling at our centre or any prenatal diagnosis). There was no clear evidence that any factor other than the presence of a previous affected child was influential.

Table 6 shows the effect of the stage of gestation at referral (this information was available for only 68 of the 81 women who declined prenatal diagnosis). Prenatal diagnosis was requested in 82% of pregnancies in which the mother was first seen before 13 weeks' gestation, and in 49% of those in which the mother was first seen in the second trimester. In 6% of cases, the woman was first seen too late in pregnancy for this option to be offered at all.

Discussion

Sickle cell disease represents a range of genetic conditions of 'intermediate' severity, in which the choice of informed couples for or against prenatal diagnosis using available technology is more or less evenly balanced. It therefore holds particular interest for research on social aspects and this study confirms its value, as it may be seen as a sensitive indicator of factors affecting service acceptability.

At risk couples referred for counselling to the UCH Perinatal Centre are first identified either by screening in antenatal clinics (prospectively), or because they already have an affected child (retrospectively). Most are first informed of their genetic risk by medical or obstetric staff, or by a haemoglobinopathy counsellor in districts where these are available, and many declining the offer of prenatal diagnosis at this stage may not be referred onwards. Thus, though about 50% of couples seen by us request prenatal diagnosis, the unbiased uptake by informed couples in London is certainly lower, probably around 30%.^{7,8} Despite this selection, analysis of the data on all couples counselled at a single prenatal diagnosis centre permits investigation of factors affecting choices.

Midtrimester prenatal diagnosis for sickle cell disease has been available since 1977.⁹ However, the data from our centre and national data (Modell *et al.*, in preparation) show that demand was insignificant until, 10 years ago, prenatal diagnosis became available before 12 weeks of pregnancy.^{10,11} The pronounced effect of stage of gestation on uptake of fetal testing observed here confirms the greater acceptability of first trimester prenatal diagnosis. However, carrier screening is still done primarily in antenatal clinics, and most couples at risk are identified too late for the

Table 4 Effect of parity and previous child with sickle cell disease on choice of PND and termination of affected pregnancy.

	Prospectively detected women (no SCD child)		Women with 1 or more SCD children	Total
	Primigravidae	Previous pregnancy		
No of women	41	93	34	168
Choosing PND	15 (37)	43 (46)	32 (94)	89 (53)
No (%)				
Diagnosis, fetus affected	4	14	15	33
Termination of pregnancy	2	12	14	28

Table 5 Previous obstetric history (primigravidae excluded): percent outcome of conceptions.

	Couples having PND	Couples not having PND
	75 women, 116 conceptions (%)	50 women, 124 conceptions (%)
SCD live births	31	4
Unaffected live births	33.5	48
Terminations (not for SCD)	21.5	23
Miscarriages	10	18.5
Stillbirth, neonatal death, etc	4	6.5

Table 6 Influence of gestational age at counselling on uptake of PND.

Gestation when woman first seen	No	Requested PND	
		No	%
Before 13 weeks	76	62	82
13–22 weeks	85	42	49
Too late for PND	11	—	—
Total	172	84	49

offer of first trimester prenatal diagnosis, and some too late to be offered it at all. There is at present some controversy on how carrier screening for autosomal recessive disorders should be offered; for example, Wald¹² considers screening in the antenatal clinic to be ideal, as “the best results are obtained by delaying carrier screening until the latest time when effective preventing action can be taken”. Our findings indicate the limitations of antenatal screening, and strongly support the Royal College of Physicians¹¹ recommendation that screening for risk of inherited disease should also be provided before pregnancy, in primary health care when possible.

The increasing availability of correct information also has a strong effect on demand for prenatal diagnosis for sickle cell disease. Before 1988, at risk couples detected in antenatal clinics were counselled by untrained medical or nursing staff, and our records show that the information given was often incomplete, incorrect, or poorly understood. Since 1988 the at risk couples we see are increasingly well informed, as more have already seen a trained haemoglobinopathy counsellor.

Direct experience of sickle cell disease within the family is also important; over 90% of the women we saw who already had an affected child chose prenatal diagnosis. Some of the children were severely affected but many were doing well: their mothers said they could

not cope with the increased anxiety associated with having two affected children. These mothers may represent a highly selected sample, as parents with affected children should in theory be well informed and only those who knew they wanted prenatal diagnosis may have been referred. However, our notes show that by no means all of them had been informed that prenatal diagnosis was available by the doctor looking after their child; some had learnt about it from a sickle cell centre, a health visitor, or a friend or other non-medical source.

The fact that half of the couples we saw where one partner actually had sickle cell disease chose prenatal diagnosis shows the ethical point that services for avoiding genetic disorders may also be used by people who have a genetic disorder themselves.

Ethnic group is also an important determinant; fewer couples of Afro-Caribbean than of African extraction requested prenatal diagnosis. The ethnic distinction is also one of social class, as many African couples are in the UK to complete advanced studies. In addition, most plan to return to Africa, where the risks associated with sickle cell disease are greatest. Most at risk couples of Cypriot or Mediterranean origin request prenatal diagnosis and terminate affected pregnancies, regardless of the stage of gestation at which they are seen.

We expected that factors in the obstetric history, such as the number of previous medical abortions, miscarriages, stillbirths, or neonatal deaths, would influence choice, but there was little evidence for this. However, primigravidae were least likely to request prenatal diagnosis.

All couples declining prenatal diagnosis said they were pleased they had been informed of their risk and requested a neonatal diagnosis. Consistent with the observed high rate of induced abortion in the group's previous obstetric history, an absolute objection to termination of pregnancy was rarely given as a reason for declining prenatal diagnosis. Many of the women would not consider terminating the current pregnancy because of sickle cell disease, but would have liked to know the diagnosis: they were deterred by the risk to the pregnancy. A second common reason given for declining prenatal diagnosis was fear of the procedure. Though only a few couples declined on religious grounds, it is possible that most with strong religious views had chosen not to be referred.

The partner was unknown or unavailable in three cases. When the woman is a carrier, the chance that her partner is also a carrier is 12% if he is Afro-Caribbean and 25% if he is African, so there is usually a 3 to 6% risk that the woman is actually carrying an affected fetus. It is important to inform the woman of this risk, and advisable to offer prenatal diagnosis if she is interested. Two of these carrier women expressed concern about the genetic risk, none requested prenatal diagnosis, and all requested a neonatal diagnosis.

We thank Dr Elizabeth Anionwu for constructive criticisms, and Dr John Old, who did most of the DNA analyses for first trimester prenatal diagnosis in these cases.

- 1 Royal College of Physicians. *Prenatal diagnosis and genetic screening; community and service implications*. London: The Royal College of Physicians of London, 1989.
- 2 British Society for Haematology. Guidelines for haemoglobinopathy screening. *Clin Lab Haematol* 1988;10:87-94.
- 3 Petrou M, Brugiattelli M, Old J, Ward RHT, Kwai Peng Wong, Modell B. Alpha thalassaemia hydrops fetalis in the UK: the importance of screening pregnant women of Chinese or other South East Asian or Mediterranean extraction for alpha thalassaemia trait. *Br J Obstet Gynaecol* (in press).
- 4 Modell B, Ward RHT, Fairweather DVI. Effect of introducing antenatal diagnosis on the reproductive behaviour of families at risk for thalassaemia major. *BMJ* 1980;ii:737.
- 5 Serjeant GR. *Sickle cell disease*. 3rd ed. Oxford: Oxford University Press, 1992.
- 6 Davies SC, Brozovic M. The presentation, management and prophylaxis of sickle cell disease. *Blood Rev* 1989;5:1-16.
- 7 Anionwu EN, Patel N, Kanji G, Renges H, Brozovic M. Counselling for prenatal diagnosis of sickle cell disease and β thalassaemia major: a four year experience. *J Med Genet* 1987;25:769.
- 8 Rowley PT, Loader S, Walden M. Pregnant women identified as haemoglobinopathy carriers by prenatal screening want genetic counseling and use information provided. *Birth Defects* 1988;23(5B):449-54.
- 9 Fairweather DVI, Modell B, Berdoukas V, et al. Antenatal diagnosis of thalassaemia major. *BMJ* 1978;i:350-3.
- 10 Old JM, Ward RHT, Petrou M, Karagozlu F, Modell B, Weatherall DJ. First-trimester fetal diagnosis for the haemoglobinopathies: three cases. *Lancet* 1982;ii:1413-6.
- 11 Old JM, Fitches A, Heath C, et al. First trimester fetal diagnosis for the haemoglobinopathies: report on 200 cases. *Lancet* 1986;ii:763-6.
- 12 Wald NJ. Couple screening for cystic fibrosis. *Lancet* 1991;338:1318-9.